A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
Alberto Chiappori(Moffitt Cancer Center), M. S. Berger(Duke University), Marshall T. Schreeder(Clearview Cancer Institute), Judy Schnyder(Gem Pharmaceuticals (United States)), Johnetta Blakely(Campbell Clinic), Ravi Salgia(City Of Hope National Medical Center), Quincy S. Chu, Joe Stephenson(Neurology Centers of the Carolinas), M. Moezi, Deepa S. Subramaniam(Georgetown University), Helen J. Ross(Rush University)
Cited by 51
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k